Issue navigation
Volume 10, Issue 4, July 2024
Editorial
Special focus on the new anti-diabetic drugs
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 265–266, https://doi.org/10.1093/ehjcvp/pvae039
PharmaPulse
De-escalation versus shortening of dual antiplatelet therapy
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 267–269, https://doi.org/10.1093/ehjcvp/pvae019
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 270–271, https://doi.org/10.1093/ehjcvp/pvae031
News in cardiovascular pharmacotherapy from the ACC.24 Meeting
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 272–277, https://doi.org/10.1093/ehjcvp/pvae034
Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes?
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Page 278, https://doi.org/10.1093/ehjcvp/pvae033
Original Articles
Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 279–288, https://doi.org/10.1093/ehjcvp/pvae006
Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 289–295, https://doi.org/10.1093/ehjcvp/pvae022
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 296–306, https://doi.org/10.1093/ehjcvp/pvae026
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 307–315, https://doi.org/10.1093/ehjcvp/pvae001
Beta-adrenergic blockade increases pulmonary vascular resistance and causes exaggerated hypoxic pulmonary vasoconstriction at high altitude: a physiological study
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 316–328, https://doi.org/10.1093/ehjcvp/pvae004
Reviews
Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 329–341, https://doi.org/10.1093/ehjcvp/pvae003
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 342–352, https://doi.org/10.1093/ehjcvp/pvae025
Non-coding RNA therapeutics in the treatment of heart failure
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 353–360, https://doi.org/10.1093/ehjcvp/pvae027
Viewpoint
Hypertension in pregnancy—what's new in the 2023 ESH Guidelines for the management of arterial hypertension
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Pages 361–363, https://doi.org/10.1093/ehjcvp/pvae012
Correspondence
Letter to the editor in response to Chan et al. 2023
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Page 364, https://doi.org/10.1093/ehjcvp/pvae007
Reply to Letter to the Editor by Thompson et al.
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 10, Issue 4, July 2024, Page 365, https://doi.org/10.1093/ehjcvp/pvae014
